Wedbush Weighs in on Biogen’s Q4 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Wedbush raised their Q4 2025 earnings estimates for shares of Biogen in a report released on Friday, May 2nd. Wedbush analyst L. Chico now anticipates that the biotechnology company will earn $3.95 per share for the quarter, up from their prior forecast of $3.87. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q1 2026 earnings at $4.06 EPS, Q2 2026 earnings at $4.06 EPS, Q3 2026 earnings at $3.94 EPS, Q4 2026 earnings at $3.73 EPS, FY2027 earnings at $16.97 EPS, FY2028 earnings at $20.23 EPS and FY2029 earnings at $20.95 EPS.

Several other equities analysts also recently weighed in on the company. Argus downgraded Biogen from a “buy” rating to a “hold” rating in a report on Friday, April 4th. Sanford C. Bernstein started coverage on Biogen in a report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Biogen in a research report on Monday, January 13th. Morgan Stanley dropped their target price on Biogen from $157.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. Finally, Citigroup reduced their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Twenty equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $192.70.

Biogen Trading Down 4.0 %

Shares of NASDAQ BIIB opened at $116.92 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The firm has a 50-day moving average of $129.75 and a 200 day moving average of $145.77. Biogen has a 1 year low of $110.04 and a 1 year high of $238.00. The stock has a market cap of $17.11 billion, a P/E ratio of 10.45, a price-to-earnings-growth ratio of 1.51 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.26 by ($0.24). Biogen had a net margin of 16.87% and a return on equity of 14.98%. The company had revenue of $2.43 billion for the quarter, compared to analysts’ expectations of $2.25 billion. During the same period in the previous year, the firm posted $3.67 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year.

Hedge Funds Weigh In On Biogen

Several large investors have recently modified their holdings of the stock. Larson Financial Group LLC boosted its holdings in Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 141 shares during the period. Lee Danner & Bass Inc. bought a new stake in Biogen during the 4th quarter valued at $25,000. Opal Wealth Advisors LLC purchased a new stake in shares of Biogen during the first quarter valued at about $26,000. Colonial Trust Co SC boosted its stake in Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 186 shares in the last quarter. Finally, Private Trust Co. NA boosted its holdings in Biogen by 74.8% in the first quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 98 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Insider Transactions at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.